Timeline of Merck's failure to act on removing Vioxx from the market

Written by Michael Monheit, Esquire, Monheit Law, PC

Continued from page 1
2001: "Dr. Deepak L. Bhatt, a cardiologist atrepparttar Cleveland Clinic, proposed to Merck a study of Vioxx in patients with severe chest pain. Merck declined, sayingrepparttar 119239 patients proposed forrepparttar 119240 study did not reflect typical Vioxx users." September 2001: FDA sent Merck a warning letter stating that Merck's promotional campaign for Vioxx "minimizesrepparttar 119241 potentially serious cardiovascular findings" in Vigor. Septmeber 2001: Merck required byrepparttar 119242 FDA to send letters to physicians acrossrepparttar 119243 country "to correct false or misleading impressions and information." 2001: Merck achieves $2.5 billion dollars of sales of Vioxx. 2001: Study critical of Vioxx appears in The Journal ofrepparttar 119244 American Medical Association. Data from several clinical trials of Vioxx showed that Vioxx may increaserepparttar 119245 risk of heart attack and stroke, and thatrepparttar 119246 danger from Vioxx appeared higher than other Cox-2 drugs. October 2002: Study by an epidemiologist at Vanderbilt University, found that high doses of Vioxx caused significantly more heart attacks and strokes than similar patients who were not taking high doses. 2002: Elucida Research examined Vioxx and found that Vioxx damagedrepparttar 119247 lipids and caused an increase in blood clots. Late 2002: Merck faces initial lawsuits from individuals suffering from strokes and heart attacks April 2004: Harvard Medical School found that Vioxx raisedrepparttar 119248 risk of heart attacks relative to Celebrex. June 2004: Researcher showed that Vioxx increasedrepparttar 119249 risk of hypertension. August 2004: Epidemiological study F.D.A. researcher based on Kaiser Permanente health care system data showed an increase cardiovascular risk for Vioxx. Study showed increasedrepparttar 119250 risk of heart disease 3.7 times Septmeber 2004: Merck withdraws Vioxx fromrepparttar 119251 market. October 2004: Thousands of people come forward with claims that their heart attacks and strokes had been caused by Merck's Vioxx. October 2004: "Dr. David Graham, estimates Vioxx had been associated with more than 27,000 heart attacks or deaths linked to cardiac problems." November 2004: SEC announces an investigation into Merck's misrepresentations to its investors. November 2004: Congress announces hearings into Merck's failures andrepparttar 119252 failures ofrepparttar 119253 FDA to regulate Merck. November 2004: The Justice Department launches investigations into what Merck knew and whether there was corporate/criminal malfeasance. Merck now claims that it took "prompt and decisive action" once it knew Vioxx was dangerous.

This original of this article can be found at: Monheit Law

Michael Monheit, Esquire is the managing attorney for Monheit Law, located in Philadelphia, Pennsylvania Monheit Law, P.C. concentrates its practice in the field of plaintiff personal injury cases on a contingency fee basis. They can be found at Monheit Law - Vioxx lawyer


Written by Mark B. Replogle

Continued from page 1

Such properties are often sold by investors for 25 to 100 percent returns on their investment using this method. However, past performance is no guarantee of future performance.

OTHER INVESTMENTS - As referred to above, at times it may be advisable for a client to purchase charged off accounts, judgments, and promissory notes. Such investments of course are best analyzed initially by an attorney. Plus, he can representrepparttar client when purchasing such financial instruments.


You get a specialist in this field.

I have limitedrepparttar 119238 number of clients so I haverepparttar 119239 maximum amount of time to devote to achieving your goals.

PRIVACY -- I will berepparttar 119240 only one working for you, which protects your privacy.

Another benefit for you is my experience in finding and selling properties through probate. Plus, I already know how to locate properties in tax lien or tax certificate sales as well as other methods of finding properties that are good investments.

I only charge a fixed fee. I will not agree with a client to share in their potential profits from any of their contemplated investments. One reason is such an arrangement is usually unethical or will require a lot of paperwork, extra time and money to meetrepparttar 119241 needed disclosures. My fee ranges from $5,000 to $10,000, depending onrepparttar 119242 work and goals ofrepparttar 119243 client.

I can best assist you to reach your goals through my expertise and love of research and writing. This benefit to you is seen by my having written and published two books that required no small amount of research.

By using my services you stand a great chance of making a lot of money. Which means you will have more money to fund your IRA, pay for your child’s college, or pay off other bills.


There are only three things you need to do. Email me, Attorney Mark B. Replogle, withrepparttar 119244 answers torepparttar 119245 below points:

1. What are your investment goals? 2. How much money are you going to invest? 3. Why should I represent you?

Please be specific and give me as much detail as you can at this time.

Mark B. Replogle is an attorney in private practice in California. In 2003 he served with the Marine Corps Central Command, Office of the Staff Judge Advocate in support of the war in Iraq. He is the author of Saviour Clinton, and How to Hear and Discern the Voice of God.

    <Back to Page 1
ImproveHomeLife.com © 2005
Terms of Use